4-氯-7-甲基喹啉-3-羧酸乙酯 | 50593-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-7-甲基喹啉-3-羧酸乙酯
• 英文名称: ethyl 4-chloro-7-methylquinoline-3-carboxylate
• CAS: 50593-19-6
• 化学式: C₁₃H₁₂ClNO₂
• 分子量: 249.697
• InChiKey: OXNSYUQJYGBUAZ-UHFFFAOYSA-N

物化性质

• 熔点：
  46-49 °C
• 沸点：
  346.4±37.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氯-7-甲基喹啉-3-羧酸乙酯 在 sodium hydroxide 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 反应 6.5h， 生成 1,4-dihydro-1-hydroxy-7-methyl-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Studies on biologically active haloganenated compounds. III. Synthesis and antibacterial activity of 7-fluoromethyl-1,8-naphthyridine and quinoline derivatives.

  摘要：

  制备了一些在 1-烷基-1，4-二氢-4-氧代-1，8-萘啶-3-羧酸和 1-烷基-1，4-二氢-4-氧代喹啉-3-羧酸的 C7 位上带有氟甲基的新型化合物，并对其抗菌活性进行了体外检测。在一系列喹啉类化合物中，7-氟甲基和 7-甲基衍生物的抗菌活性没有明显差异。不过，在 1，8-萘啶系列中，用氟甲基取代甲基后，活性有所提高。在 N1 取代基方面，2-氟乙基化合物的活性高于其他化合物。

  DOI：

  10.1248/cpb.30.3517
• 作为产物：
  描述：

  丙二酸,[[(3-甲基苯基)氨基]亚甲基]-,二乙基酯 在 三氯氧磷 作用下， 以 various solvent(s) 为溶剂， 反应 5.5h， 生成 4-氯-7-甲基喹啉-3-羧酸乙酯
  参考文献：
  名称：

  Structure–activity relationship investigations of the modulating effect of core substituents on the affinity of pyrazoloquinolinone congeners for the benzodiazepine receptor

  摘要：

  A series of 6- and 7-substituted-2-arylpyrazolo[4,3-c]quinolin-3-ones was synthesized and tested in vitro for binding with the benzodiazepine receptor in competition with [H-3]flunitrazepam. Electronic parameters (molecular electrostatic potential (MEP), charge distribution on the nitrogen atoms, dipole moment mu, and ionization potential (IP)) were calculated for the compounds by semi-empirical quantum chemistry methods. Lipophilicity of the compounds, expressed as logarithm of the octanol-water partition coefficient (log P), was calculated by the program Pallas. A quantitative correlation of the biological data with molecular parameters revealed a significant dependence (r = 0.95) of the activity on hydrophobic constants of the substituents, log P, and magnitude of the MEP minimum associated with the carbonyl oxygen atom. (C) 1998 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(98)00072-x

文献信息

• Thienylpyrazoloquinolines: potent agonists and inverse agonists to benzodiazepine receptors
  作者：Susumu Takada、Hirohisa Shindo、Takashi Sasatani、Nobuo Chomei、Akira Matsushita、Masami Eigyo、Kazuo Kawasaki、Shunji Murata、Yukio Takahara、Haruyuki Shintaku

  DOI：10.1021/jm00117a012

  日期：1988.9

  of magnitude higher affinity for the receptors than diazepam. Planarity was one of the structural requirements for binding to benzodiazepine receptors. The activities of agonists and inverse agonists were assessed on the basis of inhibition or facilitation of the pentylenetetrazole-induced convulsions, respectively. Thien-3-yl compounds exhibited inverse agonist activity whereas thien-2-yl analogues

  一系列2-（thien-3-yl）-和2-（thien-2-yl）-2,5-dihydro-3H-pyrazolo [4,3-c] quinolin-3的合成及构效关系-报告一个。与地西epa相比，许多化合物对受体的亲和力高1个数量级。平面度是与苯并二氮杂receptor受体结合的结构要求之一。激动剂和反向激动剂的活性分别基于戊烯四唑诱导的惊厥的抑制或促进进行评估。噻吩-3-基化合物表现出反向激动剂活性，而具有5'-烷基的噻吩-2-基类似物表现出激动剂活性。喹啉部分上的取代不增强体内活性。
• TANI, JUNICHI;MUSHIKA, YOSHITAKA;YAMAGUCHI, TOTARO, CHEM. AND PHARM. BULL., 1982, 30, N 10, 3517-3529
  作者：TANI, JUNICHI、MUSHIKA, YOSHITAKA、YAMAGUCHI, TOTARO

  DOI：——

  日期：——
• PESSON M.; LAJUDIE P. DE; ANTOINE M.; GIRARD P.; CHABASSIER S., C. R. ACAD. SCI. <CHDC-AQ>, 1975, 280, NO 22, 1385-1388
  作者：PESSON M.、 LAJUDIE P. DE、 ANTOINE M.、 GIRARD P.、 CHABASSIER S.

  DOI：——

  日期：——
• TAKADA, SUSUMU;SHINDO, HIROHISA;SASATANI, TAKASHI;CHOMEI, NOBUO;MATSUSHIT+, J. MED. CHEM., 31,(1988) N 9, C. 1738-1745
  作者：TAKADA, SUSUMU、SHINDO, HIROHISA、SASATANI, TAKASHI、CHOMEI, NOBUO、MATSUSHIT+

  DOI：——

  日期：——
• Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods
  申请人：LYCERA CORPORATION

  公开号：US20170007686A1

  公开（公告）日：2017-01-12

  The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) and provides adoptive cellular therapies using an agonist of RORγ, populations of lymphocyte cells that have been exposed to an agonist of RORγ, populations of dendritic cells that have been exposed to an agonist of RORγ, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of RORγ to a patient.